Key PointsNovo Nordisk was the first to market with a GLP-1 weight-loss shot, but lost its lead to Eli Lilly.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.
